SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One's team of investment professionals, located in the US and UK, have experience spanning basic science, drug development and commercialization. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. In its 30+ year history, SR One has invested over $1.1 billion in more than 180 companies, and its current portfolio includes over 40 private and public investments. For more information, please visit: http://www.srone.com/